High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly endemic Plasmodium populations by Ndiaye, Yaye Dié et al.
eCommons@AKU
Pathology, East Africa Medical College, East Africa
January 2017
High resolution melting: a useful field-deployable
method to measure dhfr and dhps drug resistance
in both highly and lowly endemic Plasmodium
populations
Yaye Dié Ndiaye
Cheikh Anta Diop University
Cyrille K. Diédhiou
Hospital Aristide Le Dantec
Amy K. Bei
Cheikh Anta Diop University
Baba Dieye
Cheikh Anta Diop University
Aminata Mbaye
Cheikh Anta Diop University
See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/eastafrica_fhs_mc_pathol
Part of the Pathology Commons
Recommended Citation
Ndiaye, Y. D., Diédhiou, C. K., Bei, A. K., Dieye, B., Mbaye, A., Mze, N. P., Daniels, R. F., Ndiaye, I. M., Déme, A. B., Gaye, A., Sy, M.,
Ndiaye, T., Badiane, A. S., Ndiaye, M., Premji, Z., Wirth, D. F., Mboup, S., Krogstad, D., Volkman, S. K., Ahouidi, A. D., Ndiaye, D.
(2017). High resolution melting: a useful field-deployable method to measure dhfr and dhps drug resistance in both highly and lowly
endemic Plasmodium populations. Malaria Journal, 16(153), 1-10.
Available at: http://ecommons.aku.edu/eastafrica_fhs_mc_pathol/150
Authors
Yaye Dié Ndiaye, Cyrille K. Diédhiou, Amy K. Bei, Baba Dieye, Aminata Mbaye, Nasserdine Papa Mze,
Rachel F. Daniels, Ibrahima M. Ndiaye, Awa B. Déme, Amy Gaye, Mouhamad Sy, Tolla Ndiaye, Aida S.
Badiane, Mouhamadou Ndiaye, Zul Premji, Dyann F. Wirth, Souleymane Mboup, Donald Krogstad, Sarah K.
Volkman, Ambroise D. Ahouidi, and Daouda Ndiaye
This article is available at eCommons@AKU: http://ecommons.aku.edu/eastafrica_fhs_mc_pathol/150
Ndiaye et al. Malar J  (2017) 16:153 
DOI 10.1186/s12936-017-1811-2
RESEARCH
High resolution melting: a useful 
field-deployable method to measure dhfr 
and dhps drug resistance in both highly 
and lowly endemic Plasmodium populations
Yaye Dié Ndiaye1,5*†, Cyrille K. Diédhiou2†, Amy K. Bei1,2,3,5,6, Baba Dieye1,5, Aminata Mbaye1, 
Nasserdine Papa Mze2, Rachel F. Daniels6,8, Ibrahima M. Ndiaye1, Awa B. Déme1,5, Amy Gaye1, Mouhamad Sy1, 
Tolla Ndiaye1, Aida S. Badiane1,5, Mouhamadou Ndiaye1,5, Zul Premji3,7, Dyann F. Wirth6,8, Souleymane Mboup2, 
Donald Krogstad4,5, Sarah K. Volkman5,6,8,9, Ambroise D. Ahouidi2,5† and Daouda Ndiaye1,5†
Abstract 
Background: Emergence and spread of drug resistance to every anti-malarial used to date, creates an urgent need 
for development of sensitive, specific and field-deployable molecular tools for detection and surveillance of validated 
drug resistance markers. Such tools would allow early detection of mutations in resistance loci. The aim of this study 
was to compare common population signatures and drug resistance marker frequencies between two popula-
tions with different levels of malaria endemicity and history of anti-malarial drug use: Tanzania and Sénégal. This was 
accomplished by implementing a high resolution melting assay to study molecular markers of drug resistance as 
compared to polymerase chain reaction–restriction fragment length polymorphism (PCR/RFLP) methodology.
Methods: Fifty blood samples were collected each from a lowly malaria endemic site (Sénégal), and a highly malaria 
endemic site (Tanzania) from patients presenting with uncomplicated Plasmodium falciparum malaria at clinic. Data 
representing the DHFR were derived using both PCR–RFLP and HRM assay; while genotyping data representing the 
DHPS were evaluated in Senegal and Tanzania using HRM. Msp genotyping analysis was used to characterize the 
multiplicity of infection in both countries.
Results: A high prevalence of samples harbouring mutant DHFR alleles was observed in both population using both 
genotyping techniques. HRM was better able to detect mixed alleles compared to PCR/RFLP for DHFR codon 51 in 
Tanzania; and only HRM was able to detect mixed infections from Senegal. A high prevalence of mutant alleles in 
DHFR (codons 51, 59, 108) and DHPS (codon 437) were found among samples from Sénégal while no mutations were 
observed at DHPS codons 540 and 581, from both countries. Overall, the frequency of samples harbouring either 
a single DHFR mutation (S108N) or double mutation in DHFR (C59R/S108N) was greater in Sénégal compared to 
Tanzania.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Plasmodium falciparum, the most deadly species of Plas-
modium parasites that infect humans, remains a public 
health problem with the majority of cases and deaths 
occurring in sub-Saharan Africa [1]. Anti-malarial drug 
resistance is a major public health problem that hin-
ders the control of malaria. P. falciparum resistance has 
been observed for all anti-malarial drugs used to date, 
including the artemisinin derivatives, where resistance 
has emerged in Asia [2–4]. Continuous monitoring of 
the effectiveness of anti-malarial drugs both in vivo and 
in  vitro plays a critical role in guiding treatment policy. 
Monitoring molecular markers of resistance is a quick 
and effective way to identify changes in drug resistance 
in real time. Malaria remains an important public health 
issue generally in Africa, and specifically in Sénégal and 
Tanzania, causing significant morbidity and mortality in 
infants and pregnant women [2]. In Sénégal, the epide-
miological profile is characterized by a stable endemic 
malaria, marked by a seasonal increase, with parasite 
prevalence trends having declined overall from 5.9% in 
2008 to 1.2% in 2014 [5]. However, malaria incidence 
remains elevated, especially in parts of the country where 
deaths attributable to malaria persist [6]. In contrast, 
malaria transmission in Mlandizi, Tanzania is perennial 
[7], with a high burden of malaria infection and clini-
cal disease as indicated by the 678,207 reported cases of 
malaria in 2014 that resulted in 5368 deaths from malaria 
[2].
Chloroquine (CQ) was the treatment of choice against 
the uncomplicated malaria in both Tanzania and Séné-
gal for decades. However, rising rates of CQ resistance 
led Tanzania to change its first-line treatment from CQ 
to sulfadoxine–pyrimethamine (SP) in 2001 and then to 
artemisinin-based combination therapy (ACT) in 2006 
[8]. Sénégal changed from CQ to SP-amodiaquine (AQ) 
in 2003 for use in seasonal malaria chemoprevention 
defined as the intermittent administration of full treat-
ment courses of an anti-malarial medicine to children 
during the malaria season in areas of highly seasonal 
transmission (SMC) and then to ACT as first-line treat-
ment of uncomplicated P. falciparum in 2006. SP remains 
in use for intermittent pregnancy treatment (IPT) in both 
countries [9–12].
SP is a combination of two antifolate compounds sulf-
adoxine that inhibits dihydropteroate synthetase (DHPS) 
and pyrimethamine that targets dihydrofolate reductase 
(DHFR). This combination acts synergistically against P. fal-
ciparum, and SP resistance mutations have been well docu-
mented. Mutations resulting in the following amino acid 
changes N51I, C59R, S108N and I164L have been identified 
in the dhfr gene associated with resistance to pyrimeth-
amine [13–19]. Mutations resulting in the following amino 
acid changes S436A, A437G, K540E and A613T/S in the 
dhps locus have similarly been linked to sulfadoxine resist-
ance [20–25]. Despite high levels of resistance to SP in 
many countries, this drug combination is still widely used 
for treatment of uncomplicated malaria, for preventing 
malaria in pregnant women in the context of IPT [2, 26], 
or in combination with artemisinin derivatives for SMC as 
recommended by the World Health Organization (WHO). 
Routine monitoring of genetic resistance mutations affect-
ing SP efficacy is useful in determining whether the drugs 
should continue to be used for treatment of uncomplicated 
malaria or malaria pregnancy.
Different methods have been developed to evalu-
ate the association of single nucleotide polymorphisms 
(SNPs) and specific phenotypes. Polymerase chain reac-
tion (PCR) restriction fragment length polymorphism 
(PCR–RFLP), Taqman real-time PCR with allele-spe-
cific probes, and denaturing gradient gel electrophoresis 
(DGGE) are the most commonly used techniques that are 
suitable for these types of studies [27, 28]. PCR/RFLP is 
time consuming and needs specific restriction enzymes 
for each SNP, as well as the ability to resolve and visualize 
the products using gel electrophoresis. DGGE requires 
extensive expertise that is not always available in disease 
endemic settings. Furthermore, the Taqman fluorescent 
probes are expensive and reagents expire rapidly. High-
resolution melting (HRM) analysis is a post-PCR analysis 
method designed to investigate variance in nucleic acid 
sequences [29]. Many studies have already published the 
accuracy, specificity and sensitivity of this technique, and 
its ability to detect minor alleles [30–32], and identify 
new genetic variants that can be confirmed by sequenc-
ing [29, 31]. HRM is a powerful analysis tool for large-
scale genotyping as it is rapid, low cost and easy to deploy 
in the field.
Conclusion: Here the results demonstrate that HRM is a rapid, sensitive, and field-deployable alternative technique 
to PCR–RFLP genotyping that is useful in populations harbouring more than one parasite genome (polygenomic 
infections). In this study, a high levels of resistance polymorphisms was observed in both dhfr and dhps, among 
samples from Tanzania and Sénégal. A routine monitoring by molecular markers can be a way to detect emergence of 
resistance involving a change in the treatment policy.
Keywords: Plasmodium falciparum, dhfr, dhps, HRM, PCR/RFLP, Senegal, Tanzania
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The goals of this study was to: (1) compare the results 
of HRM to those using PCR–RFLP in the context of 
drug resistance marker surveillance in a malaria endemic 
country; and, (2) to determine the prevalence of muta-
tions N51I, C59R, S108N in the dhfr gene and A437G, 
K540E, A581G, A613T/S in the dhps gene, across two 
malaria endemic settings with distinct frequencies of 
polyclonal infections (infections harbouring more than 
1 parasite genome), as determined by MSP 1 and 2 
genotyping.
Methods
Study population
This study was conducted using samples from two Afri-
can countries: Sénégal and Tanzania, with distinct 
malaria endemicity profiles. Samples from Senegal were 
collected in Thiès, an urban area located 70 km from cap-
ital city of Dakar, at the Service de Lutte Antiparasitaire 
(SLAP) clinic. In this region, malaria is hypoendemic 
with average of 0–20 infective bites per person per year 
(0 < EIR < 20) [33].
Samples from Tanzania, were collected from the 
Mlandizi Health Centre in the Kibaha coastal region 40 
km north–west of Dar es Salaam. In this area, malaria 
transmission is perennial, with peaks incidence occur-
ring toward the end of the long (May–July) and short 
(December–January) rains [7, 34]. Individuals seek-
ing treatment for uncomplicated P. falciparum malaria 
at the SLAP clinic in Thies in 2011 and the Mlandizi 
Health Centre in 2003–2004 were tested for malaria 
infection by microscopy. Patients between the ages of 
two and twenty who presented with only P. falciparum 
confirmed by positive blood slide were offered enroll-
ment into this study.
These studies were approved by the Tanzanian Com-
mission for Science and Technology (Permit No. 2003-
207-CC-2003-102) together the Ethics Committee of 
the Ministry of Health in Sénégal (0127MSAS/DPRS/
CNRES). Ethical review and approval was then provided 
by both the Harvard T.H. Chan School of Public Health 
Human Subjects Committee (P11778-101), and the 
Human Subjects Committee of Tulane University, New 
Orleans.
Sample collection
After informed consent, blood samples from finger-
pricks were collected and stored on Whatman FTA fil-
ter papers prior to treatment with SP in Tanzania (2003) 
and ACT (artemether–lumefantrine) in Sénégal (2011), 
according to the directives of the WHO and Ministry of 
Health in both countries, at the time of collection. Fifty 
samples from each country were randomly selected for 
DNA extraction and further genetic analyses.
DNA extraction
Genomic DNA was extracted from filter paper using the 
QIAamp DNA Mini kit (Qiagen) method. The extraction 
protocol for filter paper samples was performed and all 
samples were processed in the same way. Extracted DNA 
was stored at −20  °C until tested by PCR–RFLP and 
HRM.
Genotyping methods
Polymerase chain reaction restriction fragment length 
polymorphism (PCR–RFLP)
Sample analysis was based on the standardized polymer-
ase chain reaction and restriction fragment length poly-
morphism method, as previously described [35]. After 
PCR amplification, 0.5 unit of site specific restriction 
enzymes were used to digest the PCR amplicons over-
night as described previously by Jelinek et al. [35]. Posi-
tive (3D7 and Dd2) and negative non-template controls 
were included in all amplification and restriction digest 
procedures.
High resolution melting (HRM)
The reaction was performed on a LightScanner-32 car-
ousel platform using primers and probes as previously 
described [29]. Glass capillaries were used with a 10  µl 
final volume. Combining both mutant allele amplifica-
tion bias (MAAB) [29] and glass capillaries are ideal for 
measuring low minor allele frequencies (0.01%) in mixed 
genomic samples, which was one of the goals of this 
analysis. All PCR reactions were performed using 2.5× 
LightScanner master mix (Biofire), with forward prim-
ers at a final concentration of 0.05  µM, reverse primers 
at a final concentration of 0.2 µM (asymmetric PCR), and 
allele specific probes at a final concentration of 0.2 µM, 
and 1 µl of genomic DNA, as previously described [29]. 
Standard software included with the instruments was 
used for unlabeled probe analysis to visualize melting 
peaks based on different melting temperatures, indicative 
of different base pairs, and compared with controls to call 
alleles for a given assay.
msp genotyping
Block 2 of msp1 [36] and block 3 of msp2 [37] were ampli-
fied by nested PCR. The sequence of the primers and the 
protocol of PCR are described in detail by Snounou et al. 
[38]. Briefly, PCR was carried out in a total volume of 
20  µl that contained 6  µl Gotaq (Taq DNA polymerase, 
dNTPs,  MgCl2 and reaction buffer (pH 8.5), 0.05 µM of 
each primer and 11 µl of reagent grade water. For the first 
round of amplification, 1 µl of genomic DNA was added 
as a template and for the second round 1 µl of the PCR 
product from the first round was added. Reference strain 
3D7 (msp1-K1 and msp2-IC); Dd2 (msp1-MAD20 and 
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msp2-FC) and 7G8 (msp1-RO) were used as positive con-
trols. Reagent grade water was used as negative control. 
Products were analysed based on size differences on a 
2% agarose gel. The multiplicity of infection (MOI) was 
defined as the greater number of alleles for either msp1 
or msp2 from a single sample.
The number of patients with more than one ampli-
fied PCR fragment within the total population is defined 
as the frequency of polyclonal infections. The parasite 
genome number was also estimated to approximate the 
number of distinct genotypes present in each sample. 
Thus, msp genotyping data were used to estimate geno-
types per patient and after that the prevalence of each 
allele was determined in both countries. However, if the 
patient presents with a mixed infection with 4 clones, the 
result was called ‘undetermined’ since it could be 1 wild-
type (WT) and 3 mutant (Mut); 2 WT and 2 Mut; or, 3 
WT and 1 Mut.
Statistical analysis
Analysis data was performed using Epi Info7. Fischer’s 
exact test was used to determine the concordance 
between PCR–RFLP and HRM and the z-test for two 
population proportions was used to compare the allele 
prevalence in each country. The Mann–Whitney U test 
was used to compare the MOI in the sample populations 
of each country. The test is significant if the p value is less 
than 0.05.
Results
Comparison to PCR/RFLP and HRM
Data from the dhfr gene corresponding to codons 51, 
59 and 108 were used to compare the concordance 
between the PCR/RFLP and HRM assays. Previous 
studies have specifically compared the sensitivity and 
accuracy of this HRM method to the gold-standard of 
sequencing amplicons, and have found HRM results to 
be 100% correspondent [29]. However, here the goal was 
to assess concordance and sensitivity, in  situations in 
which discrepancies were observed in the concordance, 
the method in which more alleles was detected was con-
sidered to be more sensitive. A total of 100 samples: 50 
samples from Sénégal and 50 from Tanzania were geno-
typed using both techniques. Sénégal and Tanzania were 
selected for the comparison as the two countries have 
different frequencies of mixed infections and potentially 
different minor alleles and frequencies. Both techniques 
were performed in a laboratory in a malaria-endemic 
country (Sénégal) to assess their performance. In this 
study, a high prevalence of mutant alleles was observed 
at codons 51, 59 and 108, with some notable differences.
In Sénégal, a high proportion of monoallelic infections 
was detected using both PCR/RFLP and HRM methods, 
but only HRM detected a low level of mixed allelic infec-
tions. In Tanzania, a country with more polygenomic 
infections, HRM was better able to detect the mixed 
alleles among samples, and the frequency of mixed allelic 
infections detected by HRM were higher than those 
obtained by PCR/RFLP at codon 51 (p = 0.005) and 59 in 
Tanzania (Table 1).
Prevalence of mutations in Senegal and Tanzania in dhfr/
dhps genes by HRM
Mutation analysis was successful at each codon analysed 
from the dhfr and dhps genes, that included the three 
codons (N51I, C59R and S108N) in dhfr and four codons 
(A437G, K540E, A581G and A613T/S) in dhps. The 
prevalence of mutations at each codon in monogenomic, 
polygenomic, and combined infections (as defined by 
MSP-typing) is shown in Table 2.
In this study, mutant alleles at codons A581G and K540E 
in dhps gene were not found in among the samples ana-
lysed from Tanzania and Sénégal, and all samples tested 
carried the wild type alleles A581 and K540, respectively. 
Table 1 Percent prevalence of dhfr alleles at codons 51, 59 and 108 from isolates collected in Senegal and Tanzania using 
nested polymerase chain reaction/restriction fragment length polymerase (PCR/RFLP) and high resolution melting (HRM)
N total number of patient
Senegal (N: 50) Tanzania (N: 50)
PCR/RFLP HRM p value PCR/RFLP HRM p value
DHFR 51 N51 1/50 (2%) 0 1 09/50 (18%) 08/50 (16%) 1
51I 49/50 (98%) 47/50 (94%) 0.6173 37/50 (74%) 26/50 (52%) 0.0365
N51 + 51I 0 3/50 (6%) 0.2424 04/50 (08%) 16/50 (32%) 0.005
DHFR 59 C59 2/50 (4%) 1/50 (2%) 1 19/50 (38%) 12/50 (24%) 0.1941
59R 48/50 (96%) 46/50 (92%) 0.6777 24/50 (48%) 22/50 (44%) 0.8411
C59 + 59R 0 3/50 (6%) 0.2424 07/50 (14%) 16/50 (32%) 0.0558
DHFR 108 S108 2/50 (4%) 0 0.4949 07/50 (14%) 07/50 (14%) 1
108N 48/50 (96%) 49/50 (98%) 1 35/50 (70%) 38/50 (76%) 0.6528
S108 + 108N 0 1/50 (2%) 1 08/50 (16%) 05/50 (10%) 0.5535
Page 5 of 10Ndiaye et al. Malar J  (2017) 16:153 
Ta
bl
e 
2 
Pr
ev
al
en
ce
 o
f m
ut
at
io
ns
 in
 d
hf
r a
nd
 d
hp
s i
n 
Se
ne
ga
l a
nd
 T
an
za
ni
a:
 m
on
og
en
om
ic
, p
ol
yg
en
om
ic
, a
nd
 c
om
bi
ne
d
M
sp
-1
 a
nd
 M
sp
-2
 ty
pi
ng
 d
at
a 
w
er
e 
co
m
bi
ne
d 
w
ith
 d
ru
g 
re
si
st
an
ce
 a
lle
le
 ty
pi
ng
 to
 d
et
er
m
in
e 
th
e 
pr
ev
al
en
ce
 o
f m
ut
at
io
ns
 a
t e
ac
h 
co
do
n 
in
 m
on
og
en
om
ic
, p
ol
yg
en
om
ic
. T
he
 z
-t
es
t f
or
 2
 p
op
ul
at
io
n 
pr
op
or
tio
ns
 w
as
 u
se
d 
to
 c
om
pa
re
 th
e 
al
le
le
 p
re
va
le
nc
e 
in
 e
ac
h 
co
un
tr
y.
 T
he
 te
st
 is
 s
ig
ni
fic
an
t i
f t
he
 p
 v
al
ue
 is
 le
ss
 th
an
 0
.0
5
G
en
es
A
lle
le
s
M
on
og
en
om
ic
 in
fe
ct
io
ns
Po
ly
ge
no
m
ic
 in
fe
ct
io
ns
Co
m
bi
ne
d 
Pr
ev
al
en
ce
 o
f m
ut
at
io
ns
Se
ne
ga
l
Ta
nz
an
ia
p 
va
lu
e
Se
ne
ga
l
Ta
nz
an
ia
p 
va
lu
e
Se
ne
ga
l
Ta
nz
an
ia
p 
va
lu
e
D
H
PS
 4
37
A
43
7
10
/2
3 
(4
3.
47
%
)
6/
14
 (4
2.
86
%
)
0.
96
81
8/
27
 (2
9.
62
%
)
12
/3
6 
(3
3.
33
%
)
0.
75
65
6
18
/5
0 
(3
6%
)
18
/5
0 
(3
6%
)
1
G
43
7
12
/2
3 
(5
2.
17
%
)
6/
14
 (4
2.
86
%
)
0.
58
16
/2
7 
(5
9.
25
%
)
11
/3
6 
(3
0.
56
%
)
0.
02
26
28
/5
0 
(5
6%
)
17
/5
0 
(3
4%
)
0.
02
71
A
43
7 
+ 
G
43
7
1/
23
 (4
.3
4%
)
2/
14
 (1
4.
29
%
)
0.
28
3/
27
 (1
1.
11
%
)
13
/3
6 
(3
6.
11
%
)
0.
02
38
2
4/
50
 (8
%
)
15
/5
0 
(3
0%
)
0.
00
51
2
D
H
PS
 5
40
K5
40
23
/2
3 
(1
00
%
)
14
/1
4 
(1
00
%
)
≥0
.0
5
27
/2
7 
(1
00
%
)
36
/3
6 
(1
00
%
)
≥0
.0
5
50
/5
0 
(1
00
%
)
50
/5
0 
(1
00
%
)
≥0
.0
5
E5
40
0/
23
 (0
%
)
0/
14
 (0
%
)
≥0
.0
5
0/
27
 (0
%
)
0/
36
 (0
%
)
≥0
.0
5
0
0
≥0
.0
5
K5
40
 +
 E
54
0
0/
23
 (0
%
)
0/
14
 (0
%
)
≥0
.0
5
0/
27
 (0
%
)
0/
36
 (0
%
)
≥0
.0
5
0
0
≥0
.0
5
D
H
PS
 5
81
A
58
1
23
/2
3 
(1
00
%
)
14
/1
4 
(1
00
%
)
≥0
.0
5
27
/2
7 
(1
00
%
)
36
/3
6 
(1
00
%
)
≥0
.0
5
50
/5
0 
(1
00
%
)
50
/5
0 
(1
00
%
)
≥0
.0
5
G
58
1
0/
23
 (0
%
)
0/
14
 (0
%
)
≥0
.0
5
0/
27
 (0
%
)
0/
36
 (0
%
)
≥0
.0
5
0
0
≥0
.0
5
A
58
1 
+ 
G
58
1
0/
23
 (0
%
)
0/
14
 (0
%
)
≥0
.0
5
0/
27
 (0
%
)
0/
36
 (0
%
)
≥0
.0
5
0
0
≥0
.0
5
D
H
PS
 6
13
A
61
3
21
/2
3 
(9
1.
30
%
)
14
/1
4 
(1
00
%
)
0.
25
84
8
26
/2
7 
(9
6.
29
%
)
36
/3
6 
(1
00
%
)
≥0
.0
5
46
/5
0 
(9
2%
)
49
/5
0 
(9
8%
)
0.
16
75
8
T/
S6
13
1/
23
 (3
.3
3%
)
0/
14
 (0
%
)
0.
42
95
2
0/
27
 (0
%
)
0/
36
 (0
%
)
≥0
.0
5
2/
50
 (4
%
)
0
0.
15
27
2
A
61
3 
+ 
T/
S6
13
1/
23
 (3
.3
3%
)
0/
14
 (0
%
)
0.
42
95
2
1/
27
 (3
.7
%
)
0/
36
 (0
%
)
0.
24
60
4
2/
50
 (4
%
)
1/
50
 (2
%
)
0.
55
52
D
H
FR
 5
1
N
51
0/
23
 (0
%
)
4/
14
 (2
8.
57
%
)
0.
00
67
2
0/
27
 (0
%
)
4/
36
 (1
1.
12
%
)
0.
07
34
6
0
09
/5
0 
(1
8%
)
0.
00
16
8
51
I
20
/2
3 
(8
6.
95
%
)
4/
14
 (2
8.
57
%
)
0.
00
03
27
/2
7 
(1
00
%
)
22
/3
6 
(6
1.
12
%
)
0.
00
02
4
47
/5
0 
(9
4%
)
37
/5
0 
(7
4%
)
0.
00
63
4
N
51
 +
 5
1I
3/
23
 (1
3.
04
%
)
6/
14
 (4
2.
86
%
)
0.
04
03
6
0/
27
 (0
%
)
10
/3
6 
(2
7.
78
%
)
0.
00
27
8
3/
50
 (6
%
)
04
/5
0 
(0
8%
)
0.
69
65
4
D
H
FR
 5
9
C
59
0/
23
 (0
%
)
4/
14
 (2
2.
57
%
)
0.
00
67
2
1/
27
 (3
.7
0%
)
8/
36
 (2
2.
22
%
)
0.
03
75
2
1/
50
 (2
%
)
19
/5
0 
(3
8%
)
0
59
R
20
/2
3 
(8
6.
95
%
)
4/
14
 (2
2.
57
%
)
0.
00
03
26
/2
7 
(9
6.
29
%
)
18
/3
6 
(5
0%
)
0.
00
01
46
/5
0 
(9
2%
)
24
/5
0 
(4
8%
)
0
C
59
 +
 5
9R
3/
23
 (1
3.
04
%
)
6/
14
 (4
2.
86
%
)
0.
04
03
6
0/
27
 (0
%
)
10
/3
6 
(2
7.
78
%
)
0.
00
88
3/
50
 (6
%
)
07
/5
0 
(1
4%
)
0.
18
35
2
D
H
FR
 1
08
S1
08
0/
23
 (0
%
)
5/
14
 (3
5.
71
%
)
0.
00
20
8
0/
27
 (0
%
)
2/
36
 (5
.5
5%
)
0.
21
49
8
0
07
/5
0 
(1
4%
)
0.
00
61
4
N
10
8
22
/2
3 
(9
5.
65
%
)
9/
14
 (6
4.
29
%
)
0.
01
20
8
27
/2
7 
(1
00
%
)
29
/3
6 
(8
0.
56
%
)
0.
01
51
49
/5
0 
(9
8%
)
35
/5
0 
(7
0%
)
0.
00
01
4
S1
08
 +
 N
10
8
1/
23
 (4
.3
5%
)
0/
14
 (0
%
)
0.
42
95
2
0/
27
 (0
%
)
5/
36
 (1
3.
89
%
)
0.
04
33
8
1/
50
 (2
%
)
08
/5
0 
(1
6%
)
0.
01
42
8
Page 6 of 10Ndiaye et al. Malar J  (2017) 16:153 
The analyses showed that, monoclonal infections were 
more common in Sénégal, with a high frequency of sin-
gle mutant alleles at codons 437 in dhps and codons 51 
(p = 0.0003), 59 (p = 0.0003) and 108 (p = 0.012) in dhfr. 
However, the vast majority of infections are polyclonal in 
Tanzania, and the frequency of mixed allele calls was also 
higher compared to Sénégal just as mixed allele was more 
represented in monogenomic infections (codons 51 and 
59 (p  =  0.04)) and polygenomic infections (codons 437 
(p = 0.02) and 51 (p = 0.002), codons 59 (p = 0.008) and 
108 (p = 0.04) (Table 2).
Typing resistance alleles by either PCR–RFLP or HRM 
yields a result for all parasite genomes in a given patient 
sample. In an attempt to tease out the number of resistant 
“genomes” in the patient population, drug resistant allele 
typing was combined with MSP typing data to determine 
the number of wild-type or mutant genomes present at 
each locus (Table 3). Overall, there were more polygen-
omic infections in Tanzania (72%) compared to Sénégal 
(54%) (Table 3), although the difference was not statisti-
cally significant. However, when considering the average 
multiplicity of infection for each site, Tanzania had a sig-
nificantly higher MOI compared to Sénégal (MOI Tanza-
nia = 2.6, compared to MOI Sénégal = 1.56; p = 0.011). 
The overall results remained unchanged whether the 
data was analysed as the resistance profile for the sample 
population (Table 2) or weighted based on the number of 
parasite genomes (Table 3).
When combining the mutant alleles into haplotypes, 
the single mutation S108 N (p = 0.01) and double muta-
tion C59R/S108N (p  =  0.005) in the dhfr gene were 
higher in Senegal than in Tanzania but the triple N51I/
C59R/S108N mutation on dhfr gene and the quadruple 
N51I/C59R/S108N dhfr and A437G dhps gene muta-
tion were more represented in Tanzania, albeit not sig-
nificantly different (Table 4). The quintuple mutation was 
not observed in either site.
Discussion
This study assessed the accuracy of HRM in comparison 
with PCR–RFLP for detecting infections of P. falcipa-
rum in two areas Mlandizi, Tanzania and Thiès, Sénégal 
Table 3 Prevalence of  mutations in  dhfr and  dhps in  Senegal and  Tanzania when  accounting for  number of  parasite 
genomes per sample
The number of parasite genotypes per patient was calculated to estimate the wild-type and mutant allele frequencies in mixed infections. Undetermined represents 
samples in which the number of genotypes cannot be precisely classified due to uncertainty (for example, if there are 4 genomes, the call could be 1 WT and 3 Mut, 2 
WT and 2 Mut, or 3 WT and 1 Mut)
Alleles Parasite genome
Senegal Tanzania p value
DHPS 437 A437 27/80 (33.75%) 42/103 (40.78%) 0.9729
G437 45/80 (56.25%) 39/103 (37.86%) 0.0131
Undetermined 8/80 (10%) 22/103 (21.36%)
DHPS 540 K540 80/80 (100%) 103/103 (100%) >0.05
E540 0/80 (0%) 0/103 (0%) >0.05
Undetermined 0/80 (0%) 0/103 (0%)
DHPS 581 A581 80/80 (100%) 103/103 (100%) >0.05
G581 0/80 (0%) 0/103 (0%) >0.05
Undetermined 0/80 (0%) 0/103 (0%)
DHPS 613 A613 75/80 (3.75%) 100/103 (97.09%) 0.2713
T/S613 2/80 (2.5%) 0/103 (0%) 0.1074
Undetermined 3/80 (3.75%) 3/103 (2.91%)
DHFR 51 N51 0/80 (0%) 21/103 (20.39%) 0
51I 77/80 (96.25%) 67/103 (65.05%) 0
Undetermined 3/80 (3.75%) 15/103 (14.56%)
DHFR 59 C59 1/80 (1.25%) 32/103 (31.07%) 0
59R 76/80 (95%) 56/103 (54.37%) 0
Undetermined 3/80 (3.75%) 15/103 (14.56%)
DHFR 108 S108 0/80 (0%) 16/103 (15.5%) 0.0002
N108 79/80 (98.75%) 87/103 (84.5%) 0.0096
Undetermined 1/80 (1.25%) 0/103 (0%)
Polyclonal infections 27/50 (54%) 36/50 (72%) 0.0628
Multiplicity of infection 78/50 (1.56) 103/50 (2.06) 0.011
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two regions with variable endemicity and transmission 
intensity.
HRM analysis is comparable to PCR–RFLP for classi-
fying SNPs; however, PCR–RFLP is laborious, time con-
suming, and requires a specific restriction enzyme for 
each SNP. This method also requires the separation of 
PCR products on a gel, which often takes hours to per-
form and increases the risk of contamination, making it 
difficult to genotype a large number of samples. Further-
more, interpretation of the digestion profiles can be sub-
jective in cases of suboptimal digestion, low DNA yields, 
faint PCR products. Here, the results demonstrate that 
even when performed in a malaria-endemic laboratory 
setting, HRM is a rapid, accurate, powerful, economic, 
and a “closed-tube” mutation typing method that detects 
sequence variation within the PCR products, and can 
detect minor alleles in a mixed genotype population of 
parasite DNA. As described by previous studies, HRM 
can identify known and novel polymorphisms, detect 
multiple genotypes, and is both sensitive and specific [29, 
30, 38–41]. This study applied the HRM technology to 
type polymorphisms in mixed genotype infections in two 
African countries.
In Tanzania, more mixed genotypes were identified 
by HRM than PCR/RFLP at codon 51 (p  =  0.005), 59 
and 108. In Sénégal, a country with fewer polygenomic 
infections, no mixed infections was observed by PCR/
RFLP, however several were detected by HRM, although 
the small number resulted in non-significant p-values 
(Table  1). These results demonstrate that HRM is more 
sensitive than PCR/RFLP and can easily detect mixed 
alleles. Since PCR–RFLP may not detect clones which are 
at low frequency in a mixed population, due to the quali-
tative nature of the assay, a minor allele could easily pass 
unnoticed. In contrast, HRM detected mixed infections 
at a higher frequency in both populations, suggesting 
that the technology of HRM to detect minor subpopula-
tions is more sensitive than PCR–RFLP. While in coun-
tries like Senegal with few polygenomic infections and a 
low multiplicity of infection, there may not be a signifi-
cant difference in the techniques; whereas, the improved 
sensitivity and ability to detect minor alleles is more pro-
nounced in sample populations such as Tanzania with a 
high prevalence of polygenomic infections and a higher 
multiplicity of infection. This makes HRM a more attrac-
tive and accurate method for typing samples from both 
countries, but especially in countries like Tanzania, 
which are characterized by a high frequency of mixed 
infections. Furthermore, the ability to detect rare, low-
frequency drug resistance alleles is likely important for 
surveillance of these markers as drug pressure is applied 
and likely to select for such variants.
As HRM was the most sensitive method evaluated, it 
was used exclusively for determining the genotype of dhfr 
and dhps genes to look at the drug resistance profiles in 
both countries. The frequency of mutant alleles at codon 
437 in dhps gene and at codons 51, 59 and 108 on dhfr 
gene associated with in vivo and in vitro to SP resistance 
[23, 42] was higher in Sénégal and Tanzania (Table  2). 
These high frequencies of mutation were observed in a 
study conducted in Dakar, Senegal [43] and in Tanzania 
[44]. The presence of mutations at codons 540, 581 on 
dhps gene was not detected in either country.
In both countries, the high prevalence of mutations in 
dhfr and dhps could be explained by the use of SP as a 
second line treatment for malaria in Senegal and first line 
in Tanzania at the time of sample collection. In Sénégal, 
SP has been used since 2003 in combination with amo-
diaquine for use as SMC for children; whereas, in Tanza-
nia, SP was introduced in 2001 as first line treatment for 
uncomplicated malaria but removed in 2006 due to the 
high level of resistance observed in vivo and in vitro. SP 
remains the mainstay drug regime for intermittent pre-
ventative treatment of pregnant women (IPTp) in both 
countries. It is very possible that the continued use of 
SP may favour stepwise selection of mutations in these 
areas, contributing to the high prevalence of mutant 
alleles observed in this study. The mutation A437G in the 
dhps gene and N51I, C59R and S108N in dhfr gene were 
more prevalent in Senegal than in Tanzania (Tables 2 and 
3), which is interesting given that there has been longer 
term SP pressure in Tanzania compared to Sénégal. It 
has been observed in some studies that SP resistance 
emerges more rapidly in low-transmission compared to 
high-transmission areas [45], and this is consistent with 
the results of this study.
One potential confounder to the more frequent resist-
ant alleles in Sénégal compared to Tanzania is the dif-
ference in the MOI between the two sites. As many 
infections in Tanzania are polygenomic and contain a 
high MOI, it is possible that the number of mutant alleles 
circulating in the population is underestimated as both 
Table 4 Prevalence of  single, double, triple, quadruple 
and quintuple mutation in Tanzania and Senegal
Mutant alleles from dhfr, dhps genes were combined to make the single 
mutation (S108N), double mutation (dhfr C59R/S108N), triple mutation (dhfr 
N51I/C59R/S108 N), quadruple mutation (dhfr N51I/C59R/S108N dhps A437G) 
and quintuple mutation (N51I/C59R/S108N dhfr and A437G/K540E dhps)
Single 
mutation 
(%)
Double 
mutation 
(%)
Triple 
mutation 
(%)
Quad-
ruple 
mutation 
(%)
Quintuple 
mutation 
(%)
Senegal 20 22 44 52 0
Tanzania 2 2 48 58 0
p value 0.01 0.005 0.84 0.7 0
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PCR-RFLP and HRM can classify alleles as mutant or 
wild-type, but cannot determine the number of alleles 
of each (just the total population profile: all wild-type, all 
mutant, or mixed). To address this challenge, msp-1 and 
msp-2 typing data was combined with drug resistance 
allele typing to determine the number of wild-type or 
mutant parasite genomes (Table 3). When accounting for 
the frequency on a parasite genome basis (rather than a 
per human basis), the results do not significantly change 
as mutant alleles are still higher in Sénégal than Tanzania.
Often, studies report combinations of mutations 
in both dhfr and dhps as a way to compare with WHO 
guidelines for continued SP use. When combining 
mutant alleles, the single mutation (dhfr S108N) and 
the double mutation (dhfr C59R/S108N) was more rep-
resented in Sénégal than in Tanzania with p = 0.01 and 
p  =  0.005 respectively (Table  4). Triple and quadruple 
mutations were not significantly different between the 
two sites, although they were high for both sample sets. 
Encouragingly, the quintuple mutation N51I/C59R/
S108N dhfr and A437G/K540E dhps gene, which is 
strongly associated with in vivo and in vitro SP resistance 
in East and Southern Africa [46, 47] was not observed, 
consistent with findings from previous studies in Sénégal 
by Ndiaye et al. [48, 49] and Wurtz et al. [43]. However, a 
recent study conducted in Sénégal found a single sample 
with the quintuple mutation [50], resulting in an over-
all population prevalence of 1.1%. In light of this result, 
continued and constant monitoring of drug resistance 
molecular markers is essential.
Conclusion
These results demonstrate the enhanced sensitivity of 
HRM assays to detect minor mutant alleles compared 
to PCR/RFLP strategies in samples derived from two 
endemic countries with different levels of malaria bur-
den. Notably, Tanzania exhibited a higher MOI compared 
to Sénégal; and DHFR mutations were more common 
among samples from Senegal, as compared to Tanza-
nia. Based upon the mutant allele frequencies and the 
absence of quintuple mutations predictive for SP resist-
ance these populations, these data indicate that SP likely 
remains efficacious for IPTp and SMC per WHO recom-
mendations. However, as very recently a sample with the 
quintuple mutation was observed in Sénégal, continued 
and constant monitoring of drug resistance molecular 
markers by robust, sensitive, and field-deployable meth-
ods like HRM is a high priority.
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